Clinical Data Showing The Potential Of Epeleuton As A Treatment For Hypertriglyceridemia And Diabetes As Well As Cardiovascular Disease Prevention Will Be Presented At The American Heart Association’s 2019 Scientific Sessions, November 16-18

Afimmune receives method of use patent allowance for Oral AF102 in the US
December 18, 2018
Show all

Clinical Data Showing The Potential Of Epeleuton As A Treatment For Hypertriglyceridemia And Diabetes As Well As Cardiovascular Disease Prevention Will Be Presented At The American Heart Association’s 2019 Scientific Sessions, November 16-18

Dublin, Ireland, 14th November 2019 – Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that results of its investigational drug Epeleuton will be presented at the American Heart Association’s (AHA) 2019 Scientific Sessions, November 16-18, in Philadelphia, PA.

Results from a recently completed randomized, double-blind, placebo-controlled Phase 2 study of Epeleuton in patients with non-alcoholic fatty liver disease (NAFLD) will be presented as a moderated poster. The presentation will discuss the primary endpoints for NAFLD and the substantial effects of Epeleuton, a novel synthetic second-generation fatty acid, on triglycerides, lipids, glycemic control and inflammation.

The presentation details can be found below:

Epeleuton, A Novel Synthetic Second-Generation N-3 Fatty Acid, Decreased Triglycerides, Improved Glycemic Control and Decreased Markers of Inflammation in a Phase 2 Exploratory Study

Moderated Poster: MDP216
Session: CM.MDP24 – Physiologic Effects of Therapeutic Agents in Diabetes
Presentation date / time: Saturday November 16, 2019, 5:20 PM, Eastern U.S. time
Authors: Moayed Hamza MB BCh, Markus Weissbach MD PhD, David Coughlan PhD, John Climax PhD DSc, Deepak L. Bhatt MD MPH
Presenting author: Dr. Moayed Hamza MB BCh, Afimmune
Award: 2019 Paul Dudley White International Scholar
Detail: https://www.abstractsonline.com/pp8/#!/7891/presentation/26876

“The data being presented at the AHA offer the first clinical insights into the potential of such second generation synthetic fatty acid derivatives. We are impressed with these results and are excited about the potential of Epeleuton as a single treatment for hypertriglyceridemia, diabetes and ultimately for the prevention of cardiovascular disease” said Afimmune’s Chief Medical Officer, Dr. Markus Weissbach, MD, PhD.

About Epeleuton
Epeleuton, previously named DS102, is 15-hydroxy eicosapentaenoic acid (15(S)-HEPE) ethyl ester, a second-generation synthetic n-3 fatty acid derivative of eicosapentaenoic acid (EPA). Epeleuton is a new chemical entity with additional therapeutic effects compared to other n-3 fatty acids.

About Afimmune
Afimmune, headquartered in Dublin, Ireland, is a clinical stage drug discovery and development company working on metabolic disorders such as dyslipidemia, type 2 diabetes, non-alcoholic steatohepatitis (NASH), and cardiovascular disease.

Contact:
Afimmune: investor.relations@afimmune.com